Related Experiment Video
Updated: Jul 13, 2026

09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)
M Capobianco1, S Malucchi, A di Sapio
1Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica - ASO S. Luigi Gonzaga, Regione Gonzole 10, I-10043, Orbassano (TO), Italy. sclerosi.multipla@sanluigi.piemonte.it
Abstract:
We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.
